JAK-inhibition in Recurrent Classical Hodgkin Lymphoma (JeRiCHO)

University of Cologne

Status and phase: Completed; Phase 2

Conditions: Recurrent Classical Hodgkin Lymphoma

Treatments: Drug: Ruxolitinib

Study type: Interventional

Funder types: Other

Identifiers

NCT02164500

JeRiCHO

Details and patient eligibility

About

The Purpose of this trial is:

• to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL
• to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Enrollment: 12 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• relapsed or refractory HL
• ECOG <= 2,
• no major organ dysfunction
• written informed consent

Exclusion criteria

• history of another primary malignancy ≤ 2 years
• female patients who are pregnant or breast feeding
• patients with a known history of HIV seropositivity
• chronic active hepatitis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Ruxolitinib

Experimental group

Treatment:

Drug: Ruxolitinib